| Size | Price | Stock |
|---|---|---|
| 5g | $7 | In-stock |
| 25g | $32 | In-stock |
| 100g | $111 | In-stock |
| 200 g | Get quote | |
| 500 g | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-118594 |
| M.Wt: | 267.32 |
| Formula: | C14H21NO4 |
| Purity: | >98 % |
| Solubility: | DMSO : 100 mg/mL (ultrasonic) |
Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate is an orally active porphyrin inducer and ferrochelatase inhibitor. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can induce small bile duct obstruction in mice, resulting in blocked bile excretion and causing cholestasis. Long-term use of Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can cause damage to bile duct epithelial cells, inflammatory responses, and liver fibrosis. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can be used to simulate the pathological features of cholestatic liver diseases such as sclerosing cholangitis (PSC)[1][2][3][4][5][6].
In Vivo:Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate (0.17%; fed; continuously for 10 weeks) in 1-month-old male C3H mice induces the formation of Mallory Denk bodies (MDB). Refeeding Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate after drug withdrawal increases the proportion of FAT10-positive hepatocytes. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate also alters the expression of tumor-related genes, and liver tumors form in mice after long-term drug withdrawal[1].
Diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate (20 mg/100 g body weight; intraperitoneal injection; once, 4 h before Phenobarbital, Phorone, or Hemin (HY-19424) administration) blocks heme synthesis, prevents the induction of HO-1 by oxidative stress, and inhibits the increase in serum iron induced by phenobarbital in C57BL/6 mice with selenium deficiency or sufficiency[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information
Your information is safe with us.